Oncotelic Therapeutics (OTLC) furnishes internal corporate presentation as Exhibit 99.1

Q: What event did Oncotelic Therapeutics (OTLC) report on July 13, 2026?

Oncotelic Therapeutics reported that on July 13, 2026 it presented a corporate presentation to its employees, directors, officers and advisors. The same presentation is furnished as Exhibit 99.1 to the current report.

Q: Who was the audience for Oncotelic Therapeutics’ (OTLC) corporate presentation?

The corporate presentation was delivered to employees, directors, officers and advisors of Oncotelic Therapeutics. This internal-focused audience suggests the materials provide a general corporate overview rather than a specific financing or transaction announcement.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. reports that on July 13, 2026 it delivered a corporate presentation to its employees, directors, officers and advisors. The presentation, referred to as the “Corporate Presentation,” is provided as Exhibit 99.1 to the current report.

The company states that the information furnished under Section 8.01, including Exhibit 99.1, is being furnished rather than filed for purposes of Section 18 of the Securities Exchange Act of 1934. It also clarifies that this information is not incorporated by reference into any Securities Act or Exchange Act filing, except where specifically referenced. The report is signed on behalf of the company by Vuong Trieu, Ph.D., its Chief Executive Officer.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Terms

Emerging growth company, Section 18 of the Securities Exchange Act of 1934, incorporated by reference, Exhibit 99.1

4 terms

Emerging growth company regulatory

"The registrant indicates its status as an emerging growth company."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Section 18 of the Securities Exchange Act of 1934 regulatory

"Information is furnished and shall not be deemed filed for purposes of Section 18."

incorporated by reference regulatory

"Nor be deemed incorporated by reference in any filing under the Securities Act."

Exhibit 99.1 regulatory

"A copy of the Corporate Presentation is attached as Exhibit 99.1."

Exhibit 99.1 is a label used in regulatory filings to identify a specific attached document, most often a company press release or investor presentation filed with securities regulators. For investors it matters because it marks an official, contemporaneous source of information directly tied to a filing—like the original news article pinned to a legal record—so traders and analysts treat it as an authoritative statement that can move a stock or clarify a company’s situation.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/14/2026 - 04:01 PM Accepted by SEC EDGAR 07/14/2026 - 04:00 PM

FAQ

What event did Oncotelic Therapeutics (OTLC) report on July 13, 2026?

Oncotelic Therapeutics reported that on July 13, 2026 it presented a corporate presentation to its employees, directors, officers and advisors. The same presentation is furnished as Exhibit 99.1 to the current report.

Who was the audience for Oncotelic Therapeutics’ (OTLC) corporate presentation?

The corporate presentation was delivered to employees, directors, officers and advisors of Oncotelic Therapeutics. This internal-focused audience suggests the materials provide a general corporate overview rather than a specific financing or transaction announcement.

How is Exhibit 99.1 for Oncotelic Therapeutics (OTLC) treated under the Exchange Act?

The company states that the information in Section 8.01, including Exhibit 99.1, is being furnished and not filed for purposes of Section 18 of the Exchange Act, limiting certain statutory liabilities tied to filed materials.

Is Oncotelic Therapeutics’ (OTLC) corporate presentation incorporated by reference into other SEC filings?

The company specifies that the information in Section 8.01 and Exhibit 99.1 is not incorporated by reference into Securities Act or Exchange Act filings, except where explicitly and specifically referenced.

Who signed the current report for Oncotelic Therapeutics (OTLC)?

The report was signed on behalf of Oncotelic Therapeutics by Vuong Trieu, Ph.D., serving as Chief Executive Officer. His signature indicates authorized submission of the disclosure under the Securities Exchange Act of 1934.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

July 13, 2026

ONCOTELIC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-21990

13-3679168

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

29397 Agoura Road, Suite 107

Agoura Hills, CA 91301

(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code

(650) 635-7000

Not applicable.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of class		Trading Symbols		Name of each exchange on which registered
N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 13, 2026, Oncotelic Therapeutics, Inc. (the “Company”) presented a corporate presentation (“Corporate Presentation”) to its employees, directors and officers and advisors. A copy of the Corporate Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Disclaimer.

The information in Section 8.01 of this Current Report on Form 8-K, including the information set forth in 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Corporate Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.